---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-23-000019"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2023-04-27T23:59:59+00:00"
generated_at: "2026-06-16T08:54:33.359734+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbbVie Q1 revenue $12.2B down 9.7%; GAAP EPS $0.13, adj. EPS $2.46; raises FY guidance

## Summary
- Q1 net revenues $12.225B, down 9.7% reported / 8.3% operational; GAAP diluted EPS $0.13 (down 94.8%), adj. diluted EPS $2.46 (down 22.2%).
- Immunology portfolio $5.587B (-9%); Humira $3.541B (-25.2%), Skyrizi $1.360B (+44.7%), Rinvoq $686M (+47.5%).
- Hematologic oncology $1.416B (-14%); Imbruvica $878M (-25.2%), Venclexta $538M (+13.7%).
- Raises FY 2023 adj. diluted EPS guidance from $10.62-$11.02 to $10.72-$11.12.
- Neuroscience $1.695B (+13.9%); aesthetics $1.300B (-5.4%).

## SEC filing metadata
- accession: 0001551152-23-000019
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2023-04-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000019/0001551152-23-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000019/abbv-20230427.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-23-000019
- JSON: https://secwatch.observer/filing/0001551152-23-000019.json
- Plain text: https://secwatch.observer/filing/0001551152-23-000019.txt

## Key facts
- Earnings Releases
  AbbVie Inc. reported the first quarter ended March 31, 2023 results: revenue $12.225 Billion, EPS $0.13. Guidance raised.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $12.225 Billion
  - EPS: $0.13
  - Guidance: raised
  - Result: reported results
  source text: AbbVie Reports First-Quarter 2023 Financial Results • Reports First-Quarter Diluted EPS of $0.13 on a GAAP Basis, a Decrease of 94.8 Percent; Adjusted Diluted EPS of $2.46, a Decrease of 22.2 Percent; These Results Include an Unfavorable Impact of $0.08 Per Share related to Acquired IPR&D and Milestones Expense • Delivers First-Quarter Net Revenues of $12.225 Billion, a Decrease of 9.7 Percent on a Reported Basis and 8.3 Percent on an Operational Basis
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000019/0001551152-23-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.